• Seizure disorders

Ztalmy Generic Name & Formulations

General Description

Ganaxolone 50mg/mL; oral susp; cherry flavor.

Pharmacological Class

GABAA receptor modulator.

How Supplied

Oral susp (135mL)—1, 5

Generic Availability


Ztalmy Indications


Seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).

Ztalmy Dosage and Administration

Adults and Children

<2yrs: not established. Take with food. Give 3 times daily in equally divided doses using oral syringe. ≥2yrs (≤28kg; dose based on body wt.): initially 18mg/kg/day for Days 1–7; 33mg/kg/day for Days 8–14; 48mg/kg/day for Days 15–21; then 63mg/kg/day thereafter; (>28kg): initially 450mg/day for Days 1–7; 900mg/day for Days 8–14; 1350mg/day for Days 15–21; then 1800mg/day thereafter.

Ztalmy Contraindications

Not Applicable

Ztalmy Boxed Warnings

Not Applicable

Ztalmy Warnings/Precautions


Monitor for somnolence and sedation. Monitor for depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior. Avoid abrupt cessation. Withdraw gradually. Hepatic impairment: monitor; may need lower dose. Pregnancy. Nursing mothers.

Ztalmy Pharmacokinetics

See Literature

Ztalmy Interactions


Avoid concomitant strong or moderate CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, phenobarbital, primidone); if unavoidable, consider increasing Ztalmy dose (up to max daily dose). May increase the risk of somnolence and sedation with concomitant other CNS depressants (eg, opioids, antidepressants, alcohol).

Ztalmy Adverse Reactions

Adverse Reactions

Somnolence, pyrexia, upper respiratory tract infection, salivary hypersecretion, seasonal allergy, sedation, bronchitis, influenza, gait disturbance, nasal congestion.

Ztalmy Clinical Trials

See Literature

Ztalmy Note

Not Applicable

Ztalmy Patient Counseling

See Literature